| 王伟鹏,庄靖玲,朱彦青,严汉银,邱 丹,吕亚平.重组牛碱性成纤维细胞生长因子眼用凝胶作为角膜保护剂在翼状胬肉手术中的临床应用研究[J].现代生物医学进展英文版,2023,(8):1502-1505. |
| 重组牛碱性成纤维细胞生长因子眼用凝胶作为角膜保护剂在翼状胬肉手术中的临床应用研究 |
| Clinical Application of Recombinant Bovine Basic Fibroblast Growth Factor Eye Gel as Corneal Protective Agent in Pterygium Surgery |
| Received:September 23, 2022 Revised:October 18, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.08.020 |
| 中文关键词: 角膜保护剂 翼状胬肉 重组牛碱性成纤维细胞生长因子眼用凝胶 临床疗效 |
| 英文关键词: Corneal protective agent Recombinant bovine basic fibroblast growth factor eye gel Pterygium Clinical curative effect |
| 基金项目:2019年度南通市市级科技计划（指导性）项目（MSZ19095）；江苏省科委社会发展资助项目（BS20170372） |
|
| Hits: 703 |
| Download times: 383 |
| 中文摘要: |
| 摘要 目的：探讨重组牛碱性成纤维细胞生长因子（r-bFGF）眼用凝胶在翼状胬肉手术中的临床应用价值。方法：按照随机数字表法，将我院2019年1月~2020年12月期间收治的100例翼状胬肉手术患者分为对照组（n=50）和研究组（n=50）。手术方式均采用翼状胬肉切除联合结膜瓣转移术，对照组术中接受常规处理，研究组在对照组的基础上结合r-bFGF眼用凝胶。对比两组手术效果、眼表相关指标、视力、眼压、不良反应和并发症发生率。结果：两组术后3个月视觉疼痛模拟评分（VAS）、眼表疾病指数（OSDI）下降，泪膜破裂时间（BUT）、基础泪液分泌试验（SIT）升高（P<0.05），研究组术后3个月VAS、OSDI低于对照组，BUT、SIT高于对照组（P<0.05）。两组术后3个月视力升高，眼压下降（P<0.05），研究组术后3个月视力高于对照组，眼压低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。研究组的临床治愈率较对照组高（P<0.05）。研究组的并发症发生率低于对照组（P<0.05）。结论：r-bFGF眼用凝胶用于翼状胬肉手术中，可减少翼状胬肉患者的术后痛苦，改善眼角、视力和眼压症状，获得更好的临床治愈率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical application value of recombinant bovine basic fibroblast growth factor（r-bFGF）eye gel as corneal protective agent in pterygium surgery. Methods: 100 patients with pterygium surgery who were admitted to our hospital from January 2019 to December 2020 were selected, and they were divided into control group (n=50) and study group (n=50) according to the random number table method. Pterygium excision combined with conjunctival flap transfer was used in all operations. The control group received routine treatment during operation, and the study group was combined with r-bFGF eye gel on the basis of the control group. The operation effect, ocular surface related indicators, visual acuity, intraocular pressure, adverse reactions and incidence of complications were compared in the two groups. Results: The visual pain simulation score (VAS) and ocular surface disease index (OSDI) in the two groups at 3 months after operation decreased, tear film rupture time (BUT) and basic tear secretion test (SIT) increased (P<0.05). The VAS and OSDI in the study group at 3 months after operation were lower than those in the control group, and BUT and SIT were higher than those in control group (P<0.05). The visual acuity in the two groups at 3 months after operation increased, and the intraocular pressure decreased (P<0.05). The visual acuity in the study group at 3 months after operation was higher than that in the control group, and the intraocular pressure was lower than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions in two groups (P>0.05). The clinical cure rate in study group was significantly higher than that in control group (P<0.05). The complication rate in the study group was lower than that in control group (P<0.05). Conclusion: Recombinant bovine basic fibroblast growth factor eye gel can be used as corneal protective agent in pterygium surgery, which can reduce the postoperative pain of pterygium patients, improve the symptoms of canthus, visual acuity and intraocular pressure, and obtain a better clinical cure rate. |
|
View Full Text
View/Add Comment Download reader |
| Close |
